Venus Remedies Holds Talks With Three MNCs Over Its New Anti-infective Sulbactomax
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Venus Remedies has opened dialogue with three multinational companies to hammer out a marketing and supply deal for a combination anti-infective drug Sulbactomax that it says is "capable of replacing a larger share of the most preferred ceftriaxone world market.
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)